270
Participants
Start Date
March 9, 2015
Primary Completion Date
April 15, 2016
Study Completion Date
November 12, 2021
Nivolumab
Local Institution - 0022, Brussels
Local Institution - 0060, Waratah
Local Institution - 0023, Edegem
Local Institution - 0024, Hasselt
Local Institution - 0070, Elizabeth Vale
Local Institution - 0028, New York
Local Institution, Rostock
Local Institution - 0020, Milan
Local Institution - 0042, Hamburg
Local Institution - 0050, Pavia
Local Institution - 0031, Madrid
Local Institution - 0004, Charlotte
University Cancer Blood Ctr, Athens
Local Institution - 0009, Tampere
Erlanger Oncology & Hematology - Univ. of TN, Chattanooga
Local Institution - 0032, Seville
Local Institution - 0030, Indianapolis
Ft. Wayne Med Onco-Hema Inc, Fort Wayne
Local Institution - 0017, Arezzo
Local Institution - 0052, Iowa City
GU Research Network, LLC, Omaha
Local Institution - 0043, Heidelberg
Crescent City Research Consortium, LLC, Marrero
Local Institution - 0048, Tübingen
Local Institution - 0001, Houston
Local Institution - 0016, Aurora
Local Institution - 0018, Napoli
Local Institution - 0041, München
Local Institution - 0013, Phoenix
Local Institution - 0047, Erlangen
Pacific Hematology Oncology Associates, San Francisco
Local Institution - 0051, Portland
Local Institution - 0036, Seattle
Local Institution - 0049, Erfurt
Local Institution - 0085, Bunkyo-ku
Local Institution - 0073, Bunkyo-ku
Local Institution - 0077, Bunkyo-ku
Local Institution - 0075, Shinjuku-ku
Local Institution, Yokohama
Local Institution - 0081, Tsukuba
Local Institution - 0084, Osaka-Sayama-Shi
Local Institution - 0080, Kumamoto
Local Institution - 0076, Niigata
Local Institution - 0012, Duarte
Karmanos Cancer Institute, Detroit
Local Institution - 0029, Philadelphia
Local Institution - 0059, Pittsburgh
Local Institution - 0027, Brno
Local Institution - 0026, Olomouc
Local Institution, Prague
Local Institution - 0010, Helsinki
Local Institution - 0015, Jena
Local Institution - 0021, Roma
Local Institution - 0074, Akita
Local Institution - 0083, Hirosaki-shi
Local Institution - 0078, Morioka
Local Institution - 0082, Kyoto
Local Institution - 0086, Shinjuku-ku
Local Institution, Gdansk
Local Institution - 0046, Krakow
Local Institution - 0040, Lodz
Local Institution - 0056, Szczecin
Local Institution - 0038, Wroclaw
Local Institution - 0035, Badalona-barcelona
Local Institution - 0033, Barcelona
Local Institution - 0034, Hospitalet de Llobregat - Barcelona
Local Institution - 0014, Lund
Lead Sponsor
Collaborators (1)
Ono Pharmaceutical Co. Ltd
INDUSTRY
Bristol-Myers Squibb
INDUSTRY